Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Karen Eubanks Jackson has reshaped the conversation around breast cancer for Black women in America—and now, with the ASCO ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...